Liquidia Corporation (LQDA) compared with its closest peers (MNKD, UTHR, GYRE, HRTX, MGNX): P/E 43.1 vs industry 15.1. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
MannKind: named a competitor in the 10-K; United Therapeutics: named as a competitor in the 10-K.
| Company | Market Cap | P/E |
|---|---|---|
| MannKind Corporation (MNKD) | $1.21B | 297.2 |
| United Therapeutics Corporation (UTHR) | $21.11B | 16.1 |
| Gyre Therapeutics, Inc. (GYRE) | $751.02M | 73.5 |
| Heron Therapeutics, Inc. (HRTX) | $60.75M | — |
| MacroGenics, Inc. (MGNX) | $254.80M | — |
| Karyopharm Therapeutics Inc. (KPTI) | $36.29M | — |
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.61B | — |
| Phathom Pharmaceuticals, Inc. (PHAT) | $676.33M | — |
| Zevra Therapeutics, Inc. (ZVRA) | $709.97M | 12.2 |
| Stoke Therapeutics, Inc. (STOK) | $1.81B | — |
| Stock P/E | 43.1 |
| Sector P/E (Healthcare) | 19.4 |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| vs Sector | 122.0% |
| vs Industry | 184.7% |
LQDA overview · LQDA earnings · LQDA financials · LQDA KPIs · LQDA documents · LQDA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.